A lot of factors play into staying healthy! In turn, good health can decrease the risk of developing certain illnesses. GlobeChek Enterprises is partnering with individuals to do just that.
The company conducted its first teleophthalmology pilot study at New York-Presbyterian/Columbia University Medical Center to identify asymptomatic people with vision threatening conditions. The study found that the use of the Globe was highly effective at detecting the four most common causes of blindness. Directed by Dr. Lama Al-Aswad, the study consisted of over 300 participants and the results were overwhelmingly positive.
“Our study utilized a teleophthalmology GlobeChek™ kiosk - the first in the United States - at a location with high volume and accessibility in northern Manhattan (NY) and explored its benefit and feasibility in community-based screening program,” said Lama A. Al-Aswad, MD, MPH.
Next, GlobeChek will introduce its first commercial version of Globe (ESG 1200). The Globe is more compact, easier to maneuver, and even more comprehensive than the predecessor. The Globe is capable of checking visual acuity and performing autorefraction, intraocular pressure, OCT of the optic nerve and macula, as well as external and fundus photography. With this new device being commercially available, GlobeChek is on the frontline of improving overall health with technological advancements.
The first production will go to New York, Georgia, Florida and more states in the upcoming months. Expect to see them at public hospitals, academic medical centers and airports in the foreseeable future.
We celebrate our client GlobeCheck and their innovative technique to optimize health! For more information, please visit: www.GlobeChek.com.